Food as medicine is gaining historic momentum. Consumers increasingly believe nutrition should play a larger role in healthcare. In fact, four of five Americans say health systems should offer more nutrition-based programs to treat or manage illness.
Globally, the financial toll of poor nutrition is staggering. A 2024 report from the Food and Agriculture Organization of the United Nations estimates that unhealthy dietary patterns drive 8.1 trillion dollars in hidden health costs each year across global agrifood systems.
Yet scientific validation has not kept pace with this momentum. A recent systematic review found only fourteen randomized controlled trials in the United States that tested food as medicine interventions for chronic disease.
This gap between widespread enthusiasm and limited clinical evidence is one of the biggest barriers preventing companies in this space from securing payer contracts and scaling effectively.
The momentum is real, but proof still lags
Nutrition-focused programs are expanding rapidly through health systems, Medicaid pilots, and Medicare Advantage benefits.
Across healthcare, programs built around nutrition and medically tailored meals are expanding quickly:
- Medically tailored meals and grocery programs are gaining traction
- Produce prescriptions are being tested in multiple states
- Public demand continues to grow
Despite lagging focus on evidence-based outcomes, early results show potential. Feeding America recently reported A1C reductions among participants in a food as medicine initiative.
Still, these examples are exceptions rather than the norm. Many digital nutrition and meal-based platforms rely on engagement metrics rather than clinical outcomes, creating an evidence gap that makes it difficult to win payer and investor trust.
Why most digital nutrition companies cannot prove impact
Many companies highlight engagement metrics, like number of meals delivered, recipes opened, or user satisfaction, but these data do not answer the questions key stakeholders care about, meaning they create a barrier to growth. Health plans want to see measurable changes in disease burden, medication patterns, and total cost of care. This is where most programs fall short.
Food interventions are inherently complex. The nutrient profile, preparation method, timing, portion size, and cultural relevance of meals all influence outcomes. Behavior change adds another layer, since nutrition habits depend on preference, stress, access, and family dynamics. Without careful measurement, it is almost impossible to isolate the effect of the intervention from everything else happening in a person’s life.
Clinical outcomes also take time. A1C, cholesterol, and hospitalization rates often require several months to shift, which creates pressure for early-stage companies seeking quick results for partners or investors. Adherence is inconsistent as well. Unlike medication dosing, which is precise, nutrition programs depend on voluntary behaviors that vary widely between individuals and across time.
A final challenge is measurement infrastructure. Many organizations lack systems to link their program data to clinical or claims outcomes. Without that connection, they cannot quantify their impact on disease progression or cost of care. This leaves programs stuck at the pilot stage, unable to demonstrate the level of evidence payers require.
What strong evidence actually looks like
Food as medicine programs that have a successful growth curve follow a consistent progression of evidence building. The framework below offers a useful way to organize that work, although many activities – like publications and retrospective analyses – can happen at any point in the journey. The structure below gives teams a grounded path to follow while allowing flexibility as you scale::
Early stage evidence
- Validated nutrition metrics (diet quality scores, fruit and vegetable intake)
- Adherence and engagement data
- Short-term biomarker changes
- Small case studies or pilot reports
Growth stage evidence
- Pre and post clinical outcomes
- Retrospective analysis with EMR or claims data
- Condition-specific results (such as diabetes or heart failure)
- Partnerships with health systems or academic groups
Scale stage evidence
- Randomized or quasi-randomized trials with clinical endpoints
- Cost of care and ROI analysis
- Peer-reviewed publications
- Evidence packages tailored for payer review
This stage-based evidence ladder helps companies avoid the trap of claiming clinical proof too early while still demonstrating meaningful progress.
Evidence gaps that hold companies back
Most food as medicine programs underperform not because the interventions lack value, but because their evidence strategy is unclear. The most common mistakes include:
- Claiming clinical validation based on testimonials
- Tracking process or engagement metrics instead of outcomes
- Targeting overly broad populations
- Ignoring social determinants that influence food access and behavior
- Waiting until payer conversations begin to think about evidence
- Missing the infrastructure to connect nutrition data to clinical results
Avoiding these missteps saves time, strengthens credibility, and accelerates growth.
The future of food as medicine
Building credible evidence is a long term commitment, not a single study or a one time pilot. The strongest food as medicine programs stay focused on clear outcomes, simple tracking systems, and consistent validation as they grow. With the right structure, companies can show meaningful progress at every stage and approach payer conversations with confidence while still maintaining flexibility as the evidence base develops.
Stop guessing. Start proving your clinical value.